Intrinsic value of Diplomat Pharmacy - DPLO

Previous Close

$20.24

  Intrinsic Value

$33.03

stock screener

  Rating & Target

str. buy

+63%

Previous close

$20.24

 
Intrinsic value

$33.03

 
Up/down potential

+63%

 
Rating

str. buy

We calculate the intrinsic value of DPLO stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.5

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  25.70
  23.63
  21.77
  20.09
  18.58
  17.22
  16.00
  14.90
  13.91
  13.02
  12.22
  11.50
  10.85
  10.26
  9.74
  9.26
  8.84
  8.45
  8.11
  7.80
  7.52
  7.26
  7.04
  6.83
  6.65
  6.49
  6.34
  6.20
  6.08
  5.97
Revenue, $m
  5,638
  6,970
  8,487
  10,193
  12,086
  14,168
  16,435
  18,884
  21,511
  24,312
  27,282
  30,418
  33,717
  37,177
  40,797
  44,575
  48,514
  52,614
  56,880
  61,314
  65,923
  70,712
  75,689
  80,863
  86,241
  91,834
  97,654
  103,713
  110,022
  116,596
Variable operating expenses, $m
  5,544
  6,824
  8,281
  9,920
  11,740
  13,740
  15,918
  18,271
  20,796
  23,487
  26,215
  29,228
  32,398
  35,723
  39,201
  42,832
  46,616
  50,556
  54,655
  58,916
  63,344
  67,946
  72,729
  77,699
  82,867
  88,242
  93,834
  99,656
  105,718
  112,035
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  5,544
  6,824
  8,281
  9,920
  11,740
  13,740
  15,918
  18,271
  20,796
  23,487
  26,215
  29,228
  32,398
  35,723
  39,201
  42,832
  46,616
  50,556
  54,655
  58,916
  63,344
  67,946
  72,729
  77,699
  82,867
  88,242
  93,834
  99,656
  105,718
  112,035
Operating income, $m
  94
  147
  206
  273
  347
  428
  517
  613
  715
  825
  1,067
  1,190
  1,319
  1,454
  1,596
  1,744
  1,898
  2,058
  2,225
  2,398
  2,579
  2,766
  2,961
  3,163
  3,374
  3,592
  3,820
  4,057
  4,304
  4,561
EBITDA, $m
  264
  326
  397
  477
  566
  663
  769
  884
  1,007
  1,138
  1,277
  1,423
  1,578
  1,740
  1,909
  2,086
  2,270
  2,462
  2,662
  2,869
  3,085
  3,309
  3,542
  3,784
  4,036
  4,297
  4,570
  4,853
  5,148
  5,456
Interest expense (income), $m
  5
  39
  56
  75
  96
  121
  148
  178
  210
  246
  283
  323
  366
  411
  458
  508
  560
  614
  671
  729
  791
  854
  920
  989
  1,061
  1,135
  1,212
  1,292
  1,376
  1,463
  1,553
Earnings before tax, $m
  56
  91
  131
  176
  226
  280
  339
  402
  470
  542
  744
  824
  908
  996
  1,088
  1,184
  1,284
  1,388
  1,496
  1,608
  1,724
  1,846
  1,972
  2,103
  2,239
  2,380
  2,528
  2,681
  2,841
  3,008
Tax expense, $m
  15
  25
  35
  48
  61
  76
  92
  109
  127
  146
  201
  222
  245
  269
  294
  320
  347
  375
  404
  434
  466
  498
  532
  568
  604
  643
  683
  724
  767
  812
Net income, $m
  41
  66
  96
  129
  165
  204
  247
  294
  343
  395
  543
  601
  663
  727
  794
  864
  937
  1,013
  1,092
  1,174
  1,259
  1,347
  1,439
  1,535
  1,634
  1,738
  1,845
  1,957
  2,074
  2,196

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  2,440
  3,016
  3,673
  4,410
  5,230
  6,131
  7,112
  8,171
  9,308
  10,520
  11,805
  13,162
  14,590
  16,087
  17,653
  19,288
  20,993
  22,767
  24,613
  26,532
  28,526
  30,598
  32,752
  34,990
  37,318
  39,738
  42,256
  44,878
  47,608
  50,452
Adjusted assets (=assets-cash), $m
  2,440
  3,016
  3,673
  4,410
  5,230
  6,131
  7,112
  8,171
  9,308
  10,520
  11,805
  13,162
  14,590
  16,087
  17,653
  19,288
  20,993
  22,767
  24,613
  26,532
  28,526
  30,598
  32,752
  34,990
  37,318
  39,738
  42,256
  44,878
  47,608
  50,452
Revenue / Adjusted assets
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
  2.311
Average production assets, $m
  615
  760
  925
  1,111
  1,317
  1,544
  1,791
  2,058
  2,345
  2,650
  2,974
  3,316
  3,675
  4,052
  4,447
  4,859
  5,288
  5,735
  6,200
  6,683
  7,186
  7,708
  8,250
  8,814
  9,400
  10,010
  10,644
  11,305
  11,992
  12,709
Working capital, $m
  124
  153
  187
  224
  266
  312
  362
  415
  473
  535
  600
  669
  742
  818
  898
  981
  1,067
  1,158
  1,251
  1,349
  1,450
  1,556
  1,665
  1,779
  1,897
  2,020
  2,148
  2,282
  2,420
  2,565
Total debt, $m
  1,028
  1,382
  1,785
  2,238
  2,741
  3,294
  3,896
  4,547
  5,245
  5,989
  6,778
  7,612
  8,488
  9,407
  10,369
  11,373
  12,419
  13,509
  14,642
  15,820
  17,045
  18,317
  19,640
  21,014
  22,443
  23,929
  25,475
  27,085
  28,761
  30,508
Total liabilities, $m
  1,498
  1,852
  2,255
  2,708
  3,211
  3,764
  4,367
  5,017
  5,715
  6,459
  7,248
  8,082
  8,958
  9,878
  10,839
  11,843
  12,889
  13,979
  15,112
  16,290
  17,515
  18,787
  20,110
  21,484
  22,913
  24,399
  25,945
  27,555
  29,231
  30,978
Total equity, $m
  942
  1,164
  1,418
  1,702
  2,019
  2,366
  2,745
  3,154
  3,593
  4,061
  4,557
  5,081
  5,632
  6,210
  6,814
  7,445
  8,103
  8,788
  9,500
  10,241
  11,011
  11,811
  12,642
  13,506
  14,405
  15,339
  16,311
  17,323
  18,377
  19,475
Total liabilities and equity, $m
  2,440
  3,016
  3,673
  4,410
  5,230
  6,130
  7,112
  8,171
  9,308
  10,520
  11,805
  13,163
  14,590
  16,088
  17,653
  19,288
  20,992
  22,767
  24,612
  26,531
  28,526
  30,598
  32,752
  34,990
  37,318
  39,738
  42,256
  44,878
  47,608
  50,453
Debt-to-equity ratio
  1.090
  1.190
  1.260
  1.310
  1.360
  1.390
  1.420
  1.440
  1.460
  1.470
  1.490
  1.500
  1.510
  1.510
  1.520
  1.530
  1.530
  1.540
  1.540
  1.540
  1.550
  1.550
  1.550
  1.560
  1.560
  1.560
  1.560
  1.560
  1.570
  1.570
Adjusted equity ratio
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386
  0.386

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  41
  66
  96
  129
  165
  204
  247
  294
  343
  395
  543
  601
  663
  727
  794
  864
  937
  1,013
  1,092
  1,174
  1,259
  1,347
  1,439
  1,535
  1,634
  1,738
  1,845
  1,957
  2,074
  2,196
Depreciation, amort., depletion, $m
  169
  180
  191
  204
  219
  235
  252
  271
  291
  313
  209
  233
  259
  285
  313
  342
  372
  404
  437
  471
  506
  543
  581
  621
  662
  705
  750
  796
  845
  895
Funds from operations, $m
  210
  246
  287
  333
  384
  439
  500
  565
  634
  708
  752
  835
  922
  1,012
  1,107
  1,206
  1,309
  1,417
  1,528
  1,644
  1,765
  1,890
  2,020
  2,156
  2,296
  2,443
  2,595
  2,753
  2,919
  3,091
Change in working capital, $m
  25
  29
  33
  38
  42
  46
  50
  54
  58
  62
  65
  69
  73
  76
  80
  83
  87
  90
  94
  98
  101
  105
  109
  114
  118
  123
  128
  133
  139
  145
Cash from operations, $m
  185
  217
  254
  295
  342
  394
  450
  511
  576
  647
  687
  766
  849
  936
  1,028
  1,123
  1,223
  1,327
  1,435
  1,547
  1,664
  1,785
  1,911
  2,042
  2,178
  2,320
  2,467
  2,620
  2,780
  2,946
Maintenance CAPEX, $m
  -34
  -43
  -54
  -65
  -78
  -93
  -109
  -126
  -145
  -165
  -187
  -209
  -233
  -259
  -285
  -313
  -342
  -372
  -404
  -437
  -471
  -506
  -543
  -581
  -621
  -662
  -705
  -750
  -796
  -845
New CAPEX, $m
  -128
  -145
  -165
  -186
  -206
  -227
  -247
  -267
  -286
  -305
  -324
  -342
  -360
  -377
  -395
  -412
  -429
  -447
  -465
  -483
  -502
  -522
  -543
  -564
  -586
  -610
  -634
  -660
  -688
  -717
Cash from investing activities, $m
  -162
  -188
  -219
  -251
  -284
  -320
  -356
  -393
  -431
  -470
  -511
  -551
  -593
  -636
  -680
  -725
  -771
  -819
  -869
  -920
  -973
  -1,028
  -1,086
  -1,145
  -1,207
  -1,272
  -1,339
  -1,410
  -1,484
  -1,562
Free cash flow, $m
  22
  28
  35
  44
  57
  74
  94
  118
  145
  176
  177
  215
  256
  300
  348
  398
  451
  507
  566
  627
  690
  757
  826
  897
  971
  1,048
  1,128
  1,210
  1,296
  1,385
Issuance/(repayment) of debt, $m
  307
  354
  403
  453
  503
  553
  602
  651
  698
  744
  789
  833
  877
  919
  962
  1,004
  1,046
  1,089
  1,133
  1,178
  1,224
  1,272
  1,322
  1,374
  1,429
  1,486
  1,546
  1,610
  1,676
  1,747
Issuance/(repurchase) of shares, $m
  152
  156
  158
  156
  151
  143
  131
  115
  96
  72
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  459
  510
  561
  609
  654
  696
  733
  766
  794
  816
  789
  833
  877
  919
  962
  1,004
  1,046
  1,089
  1,133
  1,178
  1,224
  1,272
  1,322
  1,374
  1,429
  1,486
  1,546
  1,610
  1,676
  1,747
Total cash flow (excl. dividends), $m
  481
  538
  596
  654
  712
  770
  828
  884
  939
  993
  966
  1,048
  1,132
  1,220
  1,309
  1,402
  1,498
  1,597
  1,699
  1,805
  1,915
  2,029
  2,148
  2,271
  2,400
  2,534
  2,674
  2,820
  2,972
  3,132
Retained Cash Flow (-), $m
  -192
  -223
  -253
  -285
  -316
  -348
  -379
  -409
  -439
  -468
  -496
  -524
  -551
  -578
  -605
  -631
  -658
  -685
  -712
  -741
  -770
  -800
  -831
  -864
  -898
  -934
  -972
  -1,012
  -1,054
  -1,098
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  289
  316
  342
  369
  396
  422
  449
  475
  500
  525
  470
  524
  581
  642
  705
  771
  840
  912
  987
  1,064
  1,145
  1,229
  1,317
  1,407
  1,502
  1,600
  1,702
  1,808
  1,918
  2,034
Discount rate, %
  7.10
  7.46
  7.83
  8.22
  8.63
  9.06
  9.51
  9.99
  10.49
  11.01
  11.57
  12.14
  12.75
  13.39
  14.06
  14.76
  15.50
  16.27
  17.09
  17.94
  18.84
  19.78
  20.77
  21.81
  22.90
  24.04
  25.25
  26.51
  27.83
  29.22
PV of cash for distribution, $m
  270
  273
  273
  269
  262
  251
  238
  222
  204
  185
  141
  132
  122
  111
  98
  85
  73
  60
  49
  39
  31
  23
  17
  12
  9
  6
  4
  2
  2
  1
Current shareholders' claim on cash, %
  90.9
  83.9
  78.6
  74.5
  71.4
  68.9
  67.1
  65.7
  64.7
  64.1
  64.1
  64.1
  64.1
  64.1
  64.1
  64.1
  64.1
  64.1
  64.1
  64.1
  64.1
  64.1
  64.1
  64.1
  64.1
  64.1
  64.1
  64.1
  64.1
  64.1

Diplomat Pharmacy, Inc. (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company's primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions. The Company provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Company offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company's patient care system is used to coordinate and track patient adherence and safety.

FINANCIAL RATIOS  of  Diplomat Pharmacy (DPLO)

Valuation Ratios
P/E Ratio 48.3
Price to Sales 0.3
Price to Book 2.2
Price to Tangible Book
Price to Cash Flow 43.6
Price to Free Cash Flow 112.6
Growth Rates
Sales Growth Rate 31%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 11.8%
Cap. Spend. - 3 Yr. Gr. Rate 25.9%
Financial Strength
Quick Ratio 0
Current Ratio 0
LT Debt to Equity 16.3%
Total Debt to Equity 24%
Interest Coverage 8
Management Effectiveness
Return On Assets 3%
Ret/ On Assets - 3 Yr. Avg. 3%
Return On Total Capital 4%
Ret/ On T. Cap. - 3 Yr. Avg. 5.5%
Return On Equity 5%
Return On Equity - 3 Yr. Avg. 8.1%
Asset Turnover 4.2
Profitability Ratios
Gross Margin 7.4%
Gross Margin - 3 Yr. Avg. 7.2%
EBITDA Margin 2.1%
EBITDA Margin - 3 Yr. Avg. 1.7%
Operating Margin 1.1%
Oper. Margin - 3 Yr. Avg. 1%
Pre-Tax Margin 0.8%
Pre-Tax Margin - 3 Yr. Avg. 0.8%
Net Profit Margin 0.6%
Net Profit Margin - 3 Yr. Avg. 0.5%
Effective Tax Rate 30.6%
Eff/ Tax Rate - 3 Yr. Avg. 38%
Payout Ratio 0%

DPLO stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the DPLO stock intrinsic value calculation we used $4485.23 million for the last fiscal year's total revenue generated by Diplomat Pharmacy. The default revenue input number comes from 0001 income statement of Diplomat Pharmacy. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our DPLO stock valuation model: a) initial revenue growth rate of 25.7% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 7.1%, whose default value for DPLO is calculated based on our internal credit rating of Diplomat Pharmacy, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Diplomat Pharmacy.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of DPLO stock the variable cost ratio is equal to 98.9%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for DPLO stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Diplomat Pharmacy.

Corporate tax rate of 27% is the nominal tax rate for Diplomat Pharmacy. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the DPLO stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for DPLO are equal to 10.9%.

Life of production assets of 14.2 years is the average useful life of capital assets used in Diplomat Pharmacy operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for DPLO is equal to 2.2%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $749.501 million for Diplomat Pharmacy - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 74.407 million for Diplomat Pharmacy is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Diplomat Pharmacy at the current share price and the inputted number of shares is $1.5 billion.

RELATED COMPANIES Price Int.Val. Rating
ABC AmerisourceBer 92.80 339.05  str.buy
LCI Lannett 3.87 42.42  str.buy
MCK McKesson 132.39 340.66  str.buy
CAH Cardinal Healt 53.19 162.77  str.buy
WBA Walgreens Boot 77.35 130.02  str.buy
CVS CVS Health 74.18 125.09  str.buy
PINC Premier 44.80 84.69  str.buy

COMPANY NEWS

▶ Diplomat Opens Facility in Arizona   [Sep-27-18 08:05AM  PR Newswire]
▶ Diplomat to Participate in Upcoming Investor Conferences   [Aug-30-18 04:05PM  PR Newswire]
▶ Diplomat Pharmaceuticals: 2Q Earnings Snapshot   [04:52PM  Associated Press]
▶ Why Diplomat Pharmacy, Inc. Stock Dropped 10.4% Today   [Jul-20-18 04:24PM  Motley Fool]
▶ Diplomat Pharmacy Integrates With New Leadership   [May-15-18 02:50PM  Motley Fool]
▶ Why Diplomat Pharmacy Stock Jumped Today   [May-10-18 01:05PM  Motley Fool]
▶ Diplomat Pharmacy in Final Stages of CEO Search Process   [May-08-18 07:00AM  PR Newswire]
▶ Diplomat Pharmaceuticals: 1Q Earnings Snapshot   [May-07-18 04:53PM  Associated Press]
▶ Edited Transcript of DPLO presentation 7-Mar-17 9:35pm GMT   [Apr-10-18 11:00AM  Thomson Reuters StreetEvents]
▶ Why Diplomat Pharmacy Sank Today   [03:47PM  Motley Fool]
▶ Diplomat Pharmaceuticals posts 4Q profit   [Feb-26-18 04:57PM  Associated Press]
▶ Diplomat Managing Rising Drug Costs to Support Patients   [Feb-21-18 05:30PM  PR Newswire]
▶ Stocks Flashing Renewed Technical Strength: Diplomat Pharmacy   [Jan-08-18 03:00AM  Investor's Business Daily]
▶ Stocks Flashing Renewed Technical Strength: Diplomat Pharmacy   [Dec-26-17 03:00AM  Investor's Business Daily]
▶ Stocks Flashing Renewed Technical Strength: Diplomat Pharmacy   [03:00AM  Investor's Business Daily]
▶ Stocks To Watch: Diplomat Pharmacy Sees Relative Strength Rating Jump To 83   [Dec-12-17 03:00AM  Investor's Business Daily]
▶ Diplomat Adds Chris Luthin as Executive Vice President   [Dec-11-17 04:15PM  PR Newswire]
▶ Why Diplomat Pharmacy Inc Fell Today   [01:58PM  Motley Fool]
▶ Diplomat Pharmacy Inc. Expands Its Offerings   [Nov-13-17 04:28PM  Motley Fool]
▶ Why Diplomat Pharmacy Inc Fell Today   [Nov-07-17 05:02PM  Motley Fool]
▶ Diplomat Pharmaceuticals posts 3Q profit   [Nov-06-17 04:39PM  Associated Press]
▶ Diplomat Pharmacy Shows Rising Price Performance With Jump To 92 RS Rating   [Nov-03-17 03:00AM  Investor's Business Daily]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.